RedX suspends Phase I/IIa of RXC004 on safety outcome

Redx Pharma plc (LSE:REDX) suspended enrollment in a Phase I/IIa trial evaluating RXC004 in patients with advanced malignancies after the first patient dosed in the trial reported "clinically significant adverse events" possibly related to on-target effects of RXC004. The company said systemic exposure of RXC004 was “significantly higher than predicted.”

Redx plans to amend the trial to include a dose-escalation design that will start at significantly lower dose levels of RXC004. The company expects the suspension to last “several months.”...